Abstract:During the last few years Antibody-Drug Conjugates (ADCs) have become one of the most active and very promising therapeutic weapons. Lessons learned from the traditional chemical conjugations (via lysine or cysteine residues of the antibodies) and the clinical studies of the developed ADCs have recently paved the way to the improvement of the conjugation technologies. Use of site-specific conjugation is considered as the promising path for improving the design and development of homogeneous ADCs with controlled Drug-Antibody ratio (DAR). Moreover, some of these conjugations can be applied to antibody fragments such as Fab, scfv and VHH for which random and chemical conjugation showed significant limitations. In this study, we identified a novel small peptide substrate (Q-tag) with high affinity and specificity of bacterial transglutaminase which can be genetically fused to different formats of antibodies of interest for the development of enzymatic site-specific conjugation we named "CovIsolink" platform. We describe the synthesis of chemically defined drugs conjugation in which the site and stoichiometry of conjugation are controlled using a genetically encoded Q-tag peptide with specific amino acids which serves as a substrate of bacterial transglutaminase. This approach has enabled the generation of homogeneous conjugates with DAR 1,7 for full IgG and 0,8 drug ratio for Fab, scfv and VHH antibody fragments without the presence of significant amounts of unconjugated antibody and fragments. As a proof of concept, Q-tagged anti Her-2 (human IgG1 (Trastuzumab) and the corresponding fragments (Fab, scfv and VHH) were engineered and conjugated with different aminated-payloads. The corresponding Cov-ADCs were evaluated in series of in vitro and in vivo assays, demonstrating similar tumor cell killing potency as Trastuzumab emtansine (Kadcyla®) even with lower drug-to-antibody ratio (DAR).

A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates

Bridged Cysteine Conjugations

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase

Cysteine-Based Coupling: Challenges and Solutions

A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.

Nickel-Catalyzed Antibody Bioconjugation

Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody-Drug Conjugates

Antibody conjugation via one and two C-terminal selenocysteines

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates Library

DNA Self-Assembly-mediated High Drug-Antibody Ratio ADC Platform for Targeted Tumor Therapy and Imaging

A Switchable Site-Specific Antibody Conjugate.

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Synthesis of site‐specific Fab‐drug conjugates using ADP‐ribosyl cyclases

Efficient and Site-specific Antibody Labeling by Strain-promoted Azide-alkyne Cycloaddition.

A combination of multiple LC-MS approaches for the comprehensive characterization of cysteine-linked ADCs

Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates